Expert Video - Which biomarkers exist for NSCLC?
Robert Winn, MD, of Virginia Commonwealth University discusses EGFR, KRAS, and ALK, three of the main biomarkers for non-small-cell lung cancers, and the importance of testing for these to deliver precision medicine. He also encourages patients to ask which additional biomarkers will be included in the test panel.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.
Please rate this content:
Animation - Understanding Biomarker Testing in NSCLC
Slide Show - Understanding Biomarker Testing in NSCLC
1.
What is 'comprehensive biomarker testing'?
2.
What is a driver mutation?
3.
How is biomarker testing carried out?
4.
When should biomarker testing be done in NSCLC?
5.
Which biomarkers exist for NSCLC?
6.
What happens if my tumor tests positive? What happens if it doesn’t test positive for a biomarker?
7.
What if I have already had a biopsy and my tumor was not tested for biomarkers?
8.
What should newly diagnosed lung cancer patients do if biomarker testing is not offered to them?
9.
Why is biomarker testing so important for certain ethnic groups, such as African Americans?
10.
How can we close the gaps to make sure all NSCLC patients get tested?
